LexDanaLexDanabeta
New SessionDrug SearchOfficial RankingsInsights
© LexDana · beta
LexDanaLexDanabeta
New SessionDrug SearchOfficial RankingsInsights
LexDanaLexDanabeta

Insights

Analysis of patent litigation, PTAB practice, prosecution and pharma IP, written on the data behind LexDana.

AllCopyright & Trade Secrets59Federal Circuit877ITC / Section 33788Patent Litigation216Patent Prosecution126Pharma & ANDA62PTAB686Supreme Court61Trademark158USPTO Policy78Unsorted257

Tagged inter partes reexaminationation · clear

PTAB

Mere Quantification of the Results of a Known Process is Not Patentable

In Southwire Co. v. Cerro Wire LLC, [2016-2287] (September 8, 2017), the Federal Circuit affirmed the PTAB’s decision in an Inter Partes reexamination that the claims of U.S. Patent No. 7,557,301 on a method of making cable are unpatentable under 35…

September 12, 2017·PTAB·2 min read
PTAB

Article III Standing Found for PTAB Appeal Where Threat of Suit

Last month, the Federal Circuit made clear that Article III standing is necessary for petitioners to appeal from adverse decisions in AIA trial proceedings in Phigenix, Inc. v. ImmunoGen, Inc. ( here ) The Phigenix decision follows an earlier decision ,…

February 11, 2017·PTAB·2 min read
Data: FDA Orange & Purple Books · prosecution & litigation metadata · read-only.